Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 17;14(16):3972.
doi: 10.3390/cancers14163972.

Recent Advances and Challenges in Cancer Immunotherapy

Chelsea Peterson  1 , Nathan Denlinger  1 , Yiping Yang  1
Affiliations
Review

Recent Advances and Challenges in Cancer Immunotherapy

Chelsea Peterson et al. Cancers (Basel). .

Abstract

Cancer immunotherapy has revolutionized the field of oncology in recent years. Harnessing the immune system to treat cancer has led to a large growth in the number of novel immunotherapeutic strategies, including immune checkpoint inhibition, chimeric antigen receptor T-cell therapy and cancer vaccination. In this review, we will discuss the current landscape of immuno-oncology research, with a focus on elements that influence immunotherapeutic outcomes. We will also highlight recent advances in basic aspects of tumor immunology, in particular, the role of the immunosuppressive cells within the tumor microenvironment in regulating antitumor immunity. Lastly, we will discuss how the understanding of basic tumor immunology can lead to the development of new immunotherapeutic strategies.

Keywords: cancer vaccine; chimeric antigen receptor (CAR)-T cell therapy; immune checkpoint inhibitor; immunotherapy; neoantigen; tumor microenvironment (TME); tumor-associated macrophages (TAMs).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Tumor microenvironment.
See this image and copyright information in PMC

References

    1. Gonzales Carazas M.M., Pinto J.A., Casado F.L. Biological bases of cancer immunotherapy. Expert Rev. Mol. Med. 2021;23:e3. doi: 10.1017/erm.2021.5. - DOI - PMC - PubMed
    1. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366:2443–2454. doi: 10.1056/NEJMoa1200690. - DOI - PMC - PubMed
    1. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., Chow L.Q., Vokes E.E., Felip E., Holgado E., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015;373:1627–1639. doi: 10.1056/NEJMoa1507643. - DOI - PMC - PubMed
    1. Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S., Tykodi S.S., Sosman J.A., Procopio G., Plimack E.R., et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2015;373:1803–1813. doi: 10.1056/NEJMoa1510665. - DOI - PMC - PubMed
    1. Beckermann K.E., Dudzinski S.O., Rathmell J.C. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 2017;35:7–14. doi: 10.1016/j.cytogfr.2017.04.003. - DOI - PMC - PubMed

LinkOut - more resources